Tatsuro Yamamoto, Masako Ishida, Nao Kodama, Yusuke Saiki, Masachika Fujiyoshi, Miki Shimada
Development of a New Method for Simultaneous Quantitation of Plasma Concentrations of Voriconazole and Voriconazole N-Oxide Using Column-Switching LC-MS/MS and Its Application in Therapeutic Drug Monitoring.
Yonago Acta Med . 2023 Aug 9;66(3):365-374.
小川 勝弘、秦 英司、太田 友樹、栢木 啓介、藤吉 正哉、島田 美樹
薬剤師による院内処方継続理由への個別対応が医薬分業推進と薬物療法適正化に与える影響
日本病院薬剤師会雑誌、60巻2号 145-150(2024)
Masako Ishida, Takeshi Kumagai, Tatsuro Yamamoto, Hiroyuki Suzuki, Kuniaki Moriki, Masachika Fujiyoshi, Kiyoshi Nagata and Miki Shimada
Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism
Yonago Acta Medica 2024;67(1):31–40
J. Matsumoto, A. Nishimoto, S. Watari, H. Ueki, S. Shiromizu, N. Iwata, T. Takeda, S. Ushio, M. Kajizono, M. Fujiyoshi, T. Koyama, M. Araki, K. Wada, Y. Zamami, Y. Nasu, N. Ariyoshi
Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expressions in the clinical outcome of renal cell carcinoma.
Molecular and Cellular Biochemistry.2022
土屋雅美、河添 仁、大西友美子、島田美樹、堀 里子 多様な進路・働き方における薬剤師のキャリアパスに対する意識調査 医療薬学 48(6) 249-258 (2022)
森木 邦明, 永瀬 怜司, 千葉 貴志, 縄田 修一, 熊井 正貴, 深水 知英, 志田 敏宏 薬剤部門に所属している薬剤師以外の者の業務実態に関するアンケート調査結果 日本病院薬剤師会雑誌 58巻7号 739-745
安達真紀子，高根 浩，井上和子，髙橋亜樹子，島田美樹 「入院中の妊婦を対象とした健康食品利用実態と薬学的管理介入内容の分析」 医薬品情報学，24(2):130-137 2022
高根 浩，森下奨太，中山 卓，中本晶大，北澤ひとみ，佐々木志保，田邊里絵，西垣智子，森本幸弘，小林香織，西村清孝，山本敏夫，安井幸恵，薮田裕介，吉田昭昌，猪木摩耶子，三好由希子，宮前文明，岸本篤人，森田俊博，藤原弘光，木山圭吾，浅野博美，長谷川千絵，門脇昭夫，木戸脇久美，長尾孝夫，千酌浩樹 カルバペネム系抗菌薬の使用量集計における分母の検討：耐性緑膿菌分離との相関に関する多施設共同後方視的研究 医療薬学 Vol.48 No.11 2022 P491-499
Kohei Kitagawa, Shusu keUekusa, Kazuhiro Matsuo, Kei Moriyama, Tatsuro Yamamoto, Yuji Yada, Masafumi Kodama, Yoshiki Kishi, Takashi Yoshio
「Risk factors for clozapine-induced central nervous system abnormalities in Japanese patients with treatment-resistant schizophrenia」 Asian Journal of Psychiatry, Volume 60, June 2021
松本徳人、三好由希子、山本達郎、島田美樹 「ワルファリン投与下の経管栄養剤の変更・中止に伴いPT-INRが著しく変動した症例」 医療薬学/47(7)364-371(2021)
高橋真巳、秦英司、本城総一郎、島田美樹 「レボドパ・カルビドパ配合経腸用液導入時に薬剤師が介入した1 症例」 日本臨床栄養代謝学会/学会誌JSPEN Vol.2 No.4 P270-276(2020)
三好 由希子、高根 浩、森下 奨太、岡田 健作、北浦 剛、千酌 浩樹 「緑膿菌耐性率に関連するカルバペネム系抗菌薬の使用評価指標の単施設後方視的調査研究」 環境感染学会誌 35巻6号P233-240(2020)
齋尾真希、秦英司、足立美菜子、武田洋平、長谷川一将、島田美樹 「膵臓癌FOLFIRINOX療法におけるコリン様症状がブチルスコポラミンの追加投与にて軽減した2症例」 日本緩和医療薬学雑誌(Jpn.J.Pharm.Palliat.Care Sci.)13:15-18(2020)
安達真紀子 森木邦明 石川由美子 椎木芳和 島田美樹 「小児患者処方の疑義照会分析を基にした1回量・製剤量処方システム導入に伴う小児投与量制限機能の構築」 日本病院薬剤師会雑誌,
55(9):1051-1058,2019
岩澤真紀子、上田 彩、錦織淳美、上塚朋子、中川直人、島田美樹、千堂年昭 「薬剤師のワーク・ライフ・バランスに関するアンケート調査」 社会薬学（Jpn. J. Soc. Pharm.) 37, 109-116 (2018)
Kabeya T, Qiu S, Hibino M, Nagasaki M, Kodama N, Iwao T, Matsunaga T
Cyclic AMP Signaling Promotes the Differentiation of Human Induced Pluripotent Stem Cells into Intestinal Epithelial Cells. Drug Metab Dispos. 2018 Oct;46(10):1411-1419.
Kanamori M, Maekawa M, Shibahara I, Saito R, Chonan M, Shimada M, Sonoda Y, Kumabe T, Watanabe M, Mano N, Tominaga T.
Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Brain Tumor Pathol. 2018 Apr;35(2):90-96.
小川勝弘，安達真紀子，涌嶋伴之助，金田達也，椎木芳和，島田美樹 「内服薬処方せんの記載方法標準化実施における医療安全対策とその評価」 日本病院薬剤師会雑誌53巻5号 Page560-566(2017)
Tatsuro Yamamoto, Kuniaki Moriki, Miki Shimada
「Development of a quantitation method for plasma concentration of voriconazole by column-switching LC-MS/MS.」 TDM研究 35,13-21 (2018)
Hiromasa Iboshi, Hiroaki Yamaguchi, Hiroyuki Suzuki, Masafumi Kikuchi, Masaki Tanaka, Shinya Takasaki, Akiko Takahashi, Masamitsu Maekawa, Miki Shimada, Yoshinori Okada and Nariyasu Mano.
「Development of a liquid chromatography-tandem mass spectrometric method for quantification of mycophenolic acid and its glucuronides in dried blood spot samples.」 Ther. Drug Monit., 39, 648-653 (2017)
Takahiro Suga, Miki Shimada, Masamitsu Maekawa, Hiroyuki Suzuki, Masaru Mori, Tatsuma Okazaki, Akira Inoue, Hiroaki Yamaguchi and Nariyasu Mano.
「A rapid and simple UHPLC-UV method for quantitative determination of erlotinib and its active metabolites OSI-420 in human serum, and its application in a non-small cell lung cancer patient.」 Chromatography, 38, 95-100 (2017)
Kazuki Abe, Hiroyuki Suzuki, Masamitsu Maekawa, Miki Shimada, Hiroaki Yamaguchi and Nariyasu Mano
「Matrix effect–corrected liquid chromatography/tandem mass-spectrometric method for determiningacylcarnitines in human urine.」 Clin. Chim. Acta, 468,187-194 (2017)
Masamitsu Maekawa, Masaru Mori, Masachika Fujiyoshi, Hisaki Suzuki, Kazunari Yanai, Aoi Noda, Masaki Tanaka, Shinya Takasaki, Masafumi Kikuchi, Kazutoshi Akasaka, Shigeki Kisara, Masaki Matsuura, Kanehiko Hisamichi, Mayumi Sato, Junichi Goto, Miki Shimada, Hiroaki Yamaguchi, and Nariyasu Mano.
「A direct injection LC/ESI-MS/MS analysis of urinary cyclophosphamide as an anticancer drug for monitoring occupational exposure.」 Chromatography, 39, 41-47 (2018)
森木邦明、島田 美樹 「処方から投薬に至る過程において病棟担当薬剤師が担うリスクマネジメント」 医療ジャーナル 53巻3号 Page881-886 (2017)
仲田佑未, 藤原弘光，上灘紳子，高根 浩，千酌浩樹.大学病院における血液培養陽性事例に関する検討.環境感染誌 31:107-112, 2016.
安達真紀子，高根 浩，篠塚和正，森木邦明，小川勝弘，金田達也，椎木芳和，島田美樹．「健康食品利用入院患者に対する薬学的介入内容の分析と管理アルゴリズムの構築」医療薬学 42：217-227，2016．
安達真紀子，細田さとみ，法正恵子，岡野淳一，三好謙一，岡崎亮太，高根 浩，島田美樹 「標準化した薬学的管理指導に基づいてサプリメント過剰摂取との因果関係が疑われる薬物性肝障害の重症化を回避した1例」New Diet Therapy，33(4)：3-12 ，2016
Hideaki Ishii, Miki Shimada, Hiroaki Yamaguchi, Nariyasu Mano.
A simultaneous determination method for 5-fluorouracil and its metabolites in human plasma with linear range adjusted by in-source collision-induced dissociation using hydrophilic interaction liquid chromatography–electrospray ionization–tandem mass spectrometry.
Biomed. Chromatogr., in press.
小川勝弘, 椎木芳和， 金田達也，高根 浩，島田美樹 「医療用医薬品の錠剤の識別コード調査と一包化調剤された持参薬の鑑別に及ぼす影響について」 医薬品情報学会学術誌
Yuriko Murai, Hiroyuki Suzuki, Masaru Mori, Hidehisa Tasaka, Naoto Suzuki, Miki Shimada, Hiroshi Sato, Noriyasu Hirasawa, Nariyasu Mano, Yoshihisa Tomioka.
Outcomes of a Long-Term Case Review Program during the On-Site Training of Pharmacy Students.
YAKUGAKU ZASSHI. 135, 917-923 (2015).
Taiki Kajiwara, Koh Miura, Shinobu Ohnuma, Miki Shimada, Toshihiro Komura, Masahide Toshima, Atsushi Kohyama, Katsuyoshi Kudoh, Sho Haneda, Hiroaki Musha, Takeshi Naitoh, Tetsuhiko Shirasaka, Michiaki Unno.
Gastrointestinal toxicities of 5-FU increase the proportion of regulatory T cells in intestinal tract: Advantages of alternate-day S-1 administration.
Int. J. Clin. Oncol., 20, 913-921 (2015).
Masamitsu Maekawa, Miki Shimada, Kousaku Ohno, Masami Togawa, Hiroshi Nittono, Takashi Iida, Alan F Hofmann, Junichi Goto, Hiroaki Yamaguchi, Nariyasu Mano.
Focused metabolomics using liquid chromatography/electrospray ionization tandem mass spectrometry for analysis of urinary conjugated cholesterol metabolites from patients with Niemann-Pick disease type C and 3β-hydroxysteroid dehydrogenase deficiency.
Ann. Clin. Biochem., 52, 576-587 (2015).
Masamitsu Takahashi, Takahiro Saito, Miyabi Ito, Chiharu Tsukada, Yuki Katono, Hiroki Hosono, Masamitsu Maekawa, Miki Shimada, Nariyasu Mano, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka.
Functional characterization of twenty-one CYP2C19 allelic variants for clopidogrel 2-oxidation.
Pharmacogenomics J., 15, 26-32 (2015).
Toshihiro Komura,, Koh Miura, Tetsuhiko Shirasaka, Shinobu Ohnuma, Miki Shimada, Taiki Kajiwara, Fumiyoshi Fujishima, Alex Philchenkov, Kei Nakagawa, Katsuyoshi Kudoh, Sho Haneda, Masahide Toshima, Atsushi Kohyama, Hiroaki Musha, Takeshi Naitoh, Chikashi Shibata, Michiaki Unno.
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.
Int. J. Clin. Oncol., 20, 117-125 (2015).
Miki Shimada, Hoshimi Okawa, Yasuteru Kondo, Takahiro Maejima, Yuta Kataoka, Kanehiko Hisamichi, Masamitsu Maekawa, Masaki Matsuura, Yuko Jin, Masaru Mori, Masamitsu Maekawa, Hiroaki Suzuki, Tooru Shimosegawa, Nariyasu Mano.
Monitoring serum levels of sorafenib and its N-oxide is essential for long-term sorafenib treatment of patients with hepatocelluer carcinoma.
Tohoku J. Exp. Med., 237, 173-182 (2015).
渡邊桂子, 菊地正史, 木皿重樹, 小笠原喜美代, 久道周彦, 石田孝宣, 鈴木直人, 村井ユリ子, 島田美樹, 富岡佳久, 石岡千加史, 眞野成康.
乳がんFEC100療法におけるホスアプレピタント注とアプレピタントカプセルの有効性の比較
医薬品相互作用研究, 39, 29-35 (2015)
Masamitsu Maekawa, Miki Shimada, Takashi Iida, Junichi Goto, Nariyasu Mano.
Tandem mass spectrometric characterization of bile acids and steroid conjugates based on low-energy collision-induced dissociation.
Steroids, 80, 80-91(2014).
Miki Shimada, Hoshimi Okawa, Takahiro Maejima, Toshiki Yanagi, Kanehiko Hisamichi, Masaki Matsuura, Kazutoshi Akasaka, MasamiTsuchiya, Yasuteru Kondo, Tooru Shimosegawa, Masaru Mori, Masamitsu Maekawa, Hiroaki Suzuki, Nariyasu Mano.
A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
Tohoku J. Exp. Med., 233, 103-112(2014).
Masamitsu Maekawa, Miki Shimada, Takashi Iida, Junichi Goto, Nariyasu Mano.
Tandem mass spectrometric characterization of bile acids and steroid conjugates based on low-energy collision-induced dissociation. Steroids, 2014, 80(1), 80-91.
Ryuichi Nishimura, Sho Nishioka, Ikuma Fujisawa, Hitoshi Shiku, Miki Shimada, Satoshi Sekiguchi, Keisei Fujimori, Akira Ushiyama, Tomokazu Matsue, Noriaki Ohuchi, Susumu Satomi, Masafumi Goto:
Tacrolimus inhibits the revascularization of isolated pancreatic islets. PLOS ONE, 8, 1-8 (2013)
Masamitsu Maekawa, Yasushi Misawa, Ayako Sotoura, Hiroaki Yamaguchi, Masami Togawa,Kousaku Ohno, Hiroshi Nittono, Genta Kakiyama, Takashi Iida, Alan F. Hofmann, Junichi Goto, Miki Shimada, Nariyasu Mano.
LC/ESI-MS/MS analysis of urinary 3β-sulfooxy-7β-N-acetylglucosaminyl-5-cholen-24-oic acid and its amides: New biomarkers for the detection of Niemann–Pick type C disease. Steroids. , 78(10), 967–972(2013).
Hiroaki Kawamoto, Yuusuke Ohmori, masamitsu Maekawa, Miki Shimada, Nariyasu Mano, and Takashi Iida.
An efficient synthesis of 4α- and 4β-hydroxy-7-dehydrocholesterol, biomarkers for patients with and animal models of the Smith-Lemli-Opitz syndrome.
Chem. Phys. Lipids, 175-176:73-78 (2013)..
Hirohiko Shinkai, Tomoyuki Koike, Miki Shimada, Kenichiro Nakagawa, Katsunori Iijima, Yotaro Matsumoto, Masamitsu Maekawa, Nariyasu Mano, and Tooru Shimosegawa.
Influence of the meal and genotype of CYP2C19 on the pharmacokinetics of proton pump inhibitors in healthy Japanese subjects.
Pharmacol. Pharm. 4, 502-509 (2013)
片岡佑太、菊地正史、中川直人、木皿重樹、高橋哉子、小笠原喜美代、我妻恭行、久道周彦、鈴木直人、村井ユリ子、富岡佳久、石岡千加史、島田美樹、眞野成康
PTX療法におけるラニチジン注とファモチジン注のアレルギー発現率の後方視的コホート研究
日本病院薬薬剤師会雑誌, 49(10), 1091-5(2013)
Saito J, Hirota T, Furuta S, Kobayashi D, Takane H, Ieiri I.Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta.PLoS One. 2013 Aug 21;8(8):e72906
Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, Taniguchi Y, Burioka N, Shimizu E, Nakamura H, Otsubo K, Ieiri I (2012) Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 77(1):16-23.
金田達也, 森木邦明, 小川勝弘, 太田友樹, 椎木芳和, 高根 浩, 大坪健司.持参薬鑑別記録の記載内容の分析および精度向上に関する考察.日本病院薬剤師会雑誌 48:1207-1211, 2012.
高根 浩, 三好由希子, 堀井俊伸.MRSA感染症治療薬のTDM実施状況と臨床効果に関する多施設共同調査研究.医療薬学 38:785-794, 2012.
廣田豪、高根浩、鰤岡直人、清水英治、中村廣繁、大坪健司、家入一郎. microRNAによるdihydropyrimidine dehydrogenase遺伝子発現抑制機構の解明. 臨床薬理の進歩 32:115-126(2011)
大谷豊司、秦 英司、涌嶋伴之助、森木邦明、岩井ちさと、佐々木七瀬、長谷川一将、栢木啓介、椎木芳和、林原、大坪健司、堅野国幸: FOLFOX/FOLFIRI療法下患者の血圧上昇. 医療薬学37（6）327-333（2011）
Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I (2011) Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother.55(5):1867-73.
佐々木智啓、高根 浩、小川勝弘、伊差川サヤカ、廣田豪、樋口 駿、大坪健司、家入一郎: Linezolidの母集団PK/PD解析 安全性・有効性を考慮した腎機能低下・肝硬変患者における用量調節必要性の検討. TDM研究 27(3)164(2010)
森田俊博、高根 浩、大坪健司、家入一郎: 食品用粘度調整剤と嚥下補助剤の体内動態への影響. 医療薬学37:13-19, 2011
金田達也、大谷誠司、高根 浩、椎木芳和、林原正和、大坪健司:一包化調剤における配合変化情報の認識度と情報提供に伴う認識度および調剤方法の変化. 医療薬学 37: 187-193 (2011).
Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I (2009) Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 63(6):1165-9
高根 浩、島田耕太郎、小川勝弘、大坪健司:ボリコナゾールによる肝障害に関するレトロスペクティブ調査. 医療薬学 35: 579-584 (2009).
金田達也、大谷誠司、林原正和、涌嶋伴之助、秦英司、椎木芳和、大坪健司:一包化調剤の現状と安定性情報の適正利用に関する評価. 日本病院薬剤師会雑誌 45: 1599-1604(2009).
水口和生、雨宮美智子、大坪健司、小口敏夫、賀勢泰子、門林宗男、川勝一雄、川添和義、木平健治、京谷庄二郎、弦間貴秀、西岡豊、早狩誠、平賀元、宮下精一郎:病院薬剤部・薬局の、整備、構造、機能基準の改定に関する研究. 日本病院薬剤師会雑誌 45(8)1001-1004(2009)
大谷豊司、秦 英司、涌嶋伴之助、森木邦明、岩井ちさと、佐々木七瀬、長谷川一将、椎木芳和、林原正和、大坪健司、堅野国幸:FOLFOX,FOLFIRI療法における血圧上昇例の検討. 日本癌治療学会誌 44(2)905(2009)
Takaki Y, Kaminou T, Shabana M, Ihara T, Otsubo K, Ogawa T (2008) Suitable Bleeding Method of Lipiodol-cisplatin in Transcatheter Arterial Embolization for Hepatocellula Carcinoma : Evaluation of Sustained Release and Accumulation Nature. Hepato-Gastroenterilogy 55:202-6.
Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I.(2008) Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics.2008 Apr;(4);415-422
金田達也,林原正和,松田吉弘,涌嶋伴之助,秦英司,椎木芳和,大坪健司:「後発医薬品への変更可」処方せんにおける後発医薬品の継続性に関する実態調査,日本病院薬剤師会雑誌,44,913-916(2008).
Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I (2007)Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 52: 117-22.
Takane H, Miyata M, Burioka N, Kurai K, Fukuoka Y, Suyama H, Shigeoka Y, Otsubo K, Ieiri I, Shimizu E(2007)Severe toxicities following irinotecan-based chemotherapy in a lung cancer patient, a homozygote for SLCO1B1*15 allele. Ther Drug Monit 29: 666-8.
金田達也、田邊靖子、椎木芳和、林原正和、大坪健司 処方せん様式変更に伴う後発医薬品への変更に関する実態調査. 日本病院薬剤師会雑誌43: 823-826 .
金田達也、田邊靖子、細川和代、涌嶋伴之助、秦 英司、椎木芳和、寺本圭、林原正和、大坪健司 鳥取大学医学部附属病院における持参薬の実態と調査業務量の分析. 医療薬学 33: 719-724 .
小川 勝弘、高根 浩、阪本 絵理子、長谷川 賢作、北野 博也、大坪 健司 MRSA中耳炎患者で塩酸バンコマシン投与後に多発したレッドマン症候群の要因解析と対応. 日本病院薬剤師会雑誌 43: - .
西岡豊，雨宮美智子、大坪健司，小口敏夫，賀勢泰子、門林宗男，川勝一雄、木平健治，京谷庄二郎，弦間貴秀、平賀 元、前川恵子、水口和生、宮下清一郎 平成18年度学術委員会学術第１小委員会報告 病院薬剤部・薬局の整備，構造，機能基準の改定に関する研究. 日本病院薬剤師会雑誌 2007;43(8):989-1018
Miyata M, Yasuda K, Burioka N, Takane H, Suyama H, Shigeoka Y, Endo M, Kurai J, Morita M, Igishi T, Shimizu E (2006) The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in asian lung cancer patients. Cancer J 12:69-72.
Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y (2006) Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79:427-39.
Shikata E, Ieiri I, Ishiguro S, Takane H, Ohgi S and Otsubo K (2006) Multiple gene polymorphisms and warfarin sensitivity. Eur J Clin Pharmacol 62:881-3
Koyanagi S, Suyama H, Kuramoto Y, Matsunaga N, Takane H, Soeda S, Shimeno H, Higuchi S and Ohdo S (2006) Glucocorticoid regulation of 24-hour oscillation in interferon receptor gene expression in mouse liver. Endocrinology 147:5034-5040.
Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K and Ieiri I (2006) Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 18:822-6.
Ieiri I, Takane H, Hirota T, Otsubo K, Higuchi S (2006) Genetic polymorphisms of drug transporters:pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin.Drug Metab.Toxicol. 2006;2(5),651-674
H Takahashi, G R Wilkinson, E A Nutescu, T Morita, M D Ritchie, M G Scordo, V Pengo, M Barban, R Padrini, I Ieiri, K Otsubo, T Kashima, S Kimura, S Kijima, H Echizen(2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and interpopulation differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americas. Pharmacogenetics and Genomics;16(2),101-110,2006
Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanbe E, Oshimura M, Terakawa N, Otsubo K, Mine K and Sugiyama Y (2005) Functional assessment of abcg2 (bcrp) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101
Burioka N, Takata M, Okano Y, Ohdo S, Fukuoka Y, Miyata M, Takane H, Endo M, Suyama H, Shimizu E (2005) Dexamethasone influences human clock gene expression in bronchial epithelium and peripheral blood mononuclear cells in vitro. Chronobiol Int 22:585-90.
Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I (2005) Rifampicin reduces the analgesic effect of transdermal fentanyl. Ann Pharmacother 39: 2139-40.
Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T (2005) Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenet Genomics 15: 851-859.
Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S and Otsubo K (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (vitamin K-dependent protein-factors II, VII, IX, and X, proteins S and C, and [gamma]-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103: 2630-2635
Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K and Echizen H (2004) 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103: 3055-3057
Hirouchi M, Suzuki H, Itodo M, Ozawa S, Sawada J, Ieiri I, Otsubo K and Sugiyama Y (2004) Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 21: 742-748
Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K and Ieiri I (2004) Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 311: 1179-1187
Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, Kobayashi K, Chiba K, Nanba E, Oshimura M, Sato T, Higuchi S and Otsubo K (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum Mol Genet 13: 2959-2969
Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K and Sugiyama Y (2004) Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.Hepatol Res 30: 91-95
Kondo C, Suzuki H, Itoida M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Otsubo K and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2 Pharm Res 21: 1895-1903
Iwai M, Suzuki H, Ieiri I, Otsubo K and Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14: 749-757
Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I (2004) Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 11: 592-596
Teshima D, Otsubo K, Makino K, Itoh Y and Oishi R (2004) Simultaneous
determination for sulfamethoxazole and torimetoprime in human plasma with
capillary zone electrophoresis. Biomed. Chromatogr. Biomed Chromatogr 18: 51-54.
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K and Sugiyama Y (2003) Polymorphisms of OATP-C(SLC21A6) and OAT3(SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73: 554-565
Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizu E, Higuchi S and Otsubo K (2003) Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31: 677-680
Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, Tashiro N, Higuchi S and Otsubo K (2003) A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 36: 1-5
Yoshida M, Ohdo S, Takane H, Tomiyoshi Y, Matsuo A, Yukawa E and Higuchi S (2003) Chronopharmacology of analgesic effect and its tolerance induced by morphine in mice. J Pharmacol Exp Ther 305: 1200-1205
Nakayasu H, Maeda M, Soda T, Iijima K, Ishimoto M, Ieiri I, Tabuchi F, Otsubo K and Nakashima K (2003) The antiplatelet anggregation effects of aspirin suppositories. Cerebrovasc Dis 16: 31-35
Teshima D, Otsubo K, Yoshida T, Itoh Y and Oishi R (2003) A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography. Biomed Chromatogr 17: 500-503.
Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S and Otsubo K (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72
Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K and Sugimachi K (2002) Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74
Urae A, Okada M, Ieiri I, Higuchi S, Hisaoka M, Tajima M, Ogihara T and Nakano S (2002) Contribution of angiotensin converting enzyme gene polymorphism to the action of angiotensin II receptor antagonist (CS-866). Jpn J Clin Pharmacol Ther 33: 37-46.
Takane H, Ohdo S, Baba R, Koyanagi S, Yukawa E and Higuchi S (2002)Relationship between 24-hour rhythm in antiviral effect of interferon-β and interferon-α/β receptor expression in mice. Jpn J Pharmacol 90: 304-312
Takata M, Burioka Ohdo S, Takane H, Terazono H, Miyata M, Sako T, Suyama H, Fukuoka Y, Tomita K and Shimizu E (2002) Daily expression of mRNAs for the mammalian clock genes Per2 and Clock in mouse suprachiasmatic nuclei and liver and human peripheral blood mononuclear cells. Jpn J Pharmacol 90: 263-269
Honda T, Dan Y, Koyabu N, Ieiri I, Otsubo K, Higuchi S, Ohtani H and Sawada Y (2002) Polymorphism of MDR1 gene in healthy Japanese subjects: a novel SNP with an amino acid substitution (Glu108Lys). Drug Metab Pharmacokin 17: 479-481.
Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H and Tashiro N (2001) Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 23: 75-77.
Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S and Otsubo K (2001) Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175-184.
Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N and Otsubo K (2001) Expression of P-glycoprotein in human Placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143.
Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K and Ishizaki T (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Pharmacol 57: 485-492.
Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S and Otsubo K (2001) Genetic polymorphism and functional characterization of the 5’-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin Pharmacol Ther 70: 175-182.
Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N and Higuchi S (2000) CYP2C19 polymorphism effect on phenobarbitone. Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55:821-825.
Shimamoto J, Ieiri I, Urae A, Kimura M, Irie S, Kubota T, Chiba K, Ishizaki T, Otsubo K and Higuchi S (2000) Lack of differences in diclofenac (a substrate for CYP2C9) pharmacikinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur J Clin Pharmacol 56: 65-68.
Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S and Tashiro N (2000) Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin cencentration with central nervous system intoxication. Ther Drug Monit 22: 230-232.
Ieiri I, Taninaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, Higuchi S and Otsubo K (2000) Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 22: 237-244.
Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, Otsubo K and Higuchi S (2000) Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10: 85-89.
Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, HiguchiS and Tashiro N (1998) The effects of genetic polymorphisms of CYP2C9 and CYPC19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39: 1317-1323.
Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, Sakai T, Otsubo K and Higuchi S (1999) Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 47: 115-119.